Allergy Asthma Proc. 2024 Sep 1;45(5):364-370. doi: 10.2500/aap.2024.45.240053.
Immunoglobulin replacement is donor-derived pooled immunoglobulin G, which provides passive immunity to patients with antibody deficiency or dysfunction. It may be administered either intravenous or subcutaneous routes. Intravenous immunoglobulin is administered at higher doses every 3-4 weeks, whereas most forms of subcutaneous immunoglobulin are administered at lower doses, usually every 1-2 weeks. Benefits and risks, including adverse effects, convenience, and cost vary according to route of administration. Immunoglobulin products also differ in their composition, so patient-specific comorbidities are important to consider when selecting an immunoglobulin product. We discuss adverse effects associated with immunoglobulin therapy, their associated risk factors, treatment, and ways to mitigate these risks. Finally, the laboratory monitoring and vaccination recommendations for patients on immunoglobulin replacement therapy are reviewed.
免疫球蛋白替代治疗使用的是供者来源的免疫球蛋白 G 制剂，为抗体缺陷或功能障碍的患者提供被动免疫。该治疗可以通过静脉输注或皮下注射途径给予。静脉输注免疫球蛋白通常每 3-4 周给予较高剂量，而大多数形式的皮下免疫球蛋白则以较低剂量给予，通常每 1-2 周一次。获益和风险（包括不良反应）、便利性和费用因给药途径而异。免疫球蛋白产品在组成上也有所不同，因此在选择免疫球蛋白产品时，需要考虑患者的具体合并症。我们讨论了与免疫球蛋白治疗相关的不良反应、相关危险因素、治疗方法以及减轻这些风险的方法。最后，我们还回顾了接受免疫球蛋白替代治疗患者的实验室监测和疫苗接种建议。
